Therefore, our data suggest that SLAMF7 agonism sensitises CD8+ T cells to checkpoint inhibition, supporting a combinatorial strategy that could broaden the efficacy of checkpoint-based tumor immunotherapy. Here, SLAMF7 is linked to neoplasm.